MedTrace Logo

the Value of Immunohistochemical Expression of Moesin in Endometrial Hyperplasia and Endometrial Carcinoma

NCT05619159 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-11-16

No results posted yet for this study

Summary

Endometrial carcinoma (EC) is the most prevalent invasive carcinoma of the female genital tract in developed countries, while it ranks as the second most frequently occurring neoplasm of women in developing countries, after carcinoma of the cervix uteri. The vast majority of ECs occur in perimenopausal and postmenopausal women .

ECs are classified into two distinct phenotypes; type I which represents more than 80% of all cases of ECs, it has a favorable prognosis. This type is linked to excess, unopposed hyper-estrogenic condition and it is almost always preceded by endometrial hyperplasia. On the contrary, type II endometrial carcinoma is less common than type I, representing less than 10% of all cases of ECs. Type II endometrial carcinomas are high grade, poorly differentiated and estrogen-independent tumors .

Conditions

  • Endometrial Cancer and Endometrial Hyperplasia

Interventions

DEVICE

microscopic pathological evaluation

description of moesin expression between endometrial hyperplasia and endometrial carcinoma

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05619159 on ClinicalTrials.gov